$PLYX

Polaryx Therapeutics, Inc. (PLYX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. Polaryx Therapeutics, Inc. (the “Company”), held its Annual Meeting of Stockholders on Thursday, September 10, 2026. For more information on the following proposals, refer to the Company’s Proxy Statement filed with

Polaryx Therapeutics, Inc. (PLYX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0002075320 0002075320 2026-07-19 2026-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Yang Alex Keun Mo (Chief Executive Officer) purchased 88,453 indirectly-held shares of Polaryx Therapeutics, Inc. (PLYX) at $4.07 ($0.36M total) on 2026-05-27.

Polaryx Therapeutics said it completed a PIPE financing of 2,502,696 shares at an average ~$4 per share, with no SEC registration statement for resale. The company plans to use $10 million gross proceeds plus existing cash to start its Phase 2 SOTERIA basket trial for PLX-200 across four LSDs, extending runway to Q2 2027. Shares were up 8.76% to $2.73.